Cite
HARVARD Citation
Deodhar, A. et al. (n.d.). THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials. Annals of the rheumatic diseases. pp. 340-341. [Online].